PARD (Poniard Pharmaceuticals) LT-Debt-to-Total-Asset: 0.21 (As of Sep. 2011)


What is Poniard Pharmaceuticals LT-Debt-to-Total-Asset?

Poniard Pharmaceuticals PARD LT-Debt-to-Total-Asset is 0.21 as of Sep. 2011.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Poniard Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2011 was 0.21.

Poniard Pharmaceuticals's long-term debt to total assets ratio increased from Sep. 2010 (0.21) to Sep. 2011 (0.21). It may suggest that Poniard Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Poniard Pharmaceuticals  (OTCPK:PARD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Poniard Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Poniard Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals LT-Debt-to-Total-Asset Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.06 0.21 0.22 0.14

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.14 0.13 0.16 0.21

Poniard Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Poniard Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2010 is calculated as

LT Debt to Total Assets (A: Dec. 2010 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2010 )/Total Assets (A: Dec. 2010 )
=1.574/11.643
=

Poniard Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2011 is calculated as

LT Debt to Total Assets (Q: Sep. 2011 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2011 )/Total Assets (Q: Sep. 2011 )
=1.64/7.736
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.21 mean?
Poniard Pharmaceuticals (PARD) has a LT-Debt-to-Total-Asset of 0.21 as of Sep. 2011. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Poniard Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.21.
How does Poniard Pharmaceuticals' LT-Debt-to-Total-Asset compare to OBMP and NSPX?
Poniard Pharmaceuticals' LT-Debt-to-Total-Asset of 0.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current LT-Debt-to-Total-Asset of 0.21. The current LT-Debt-to-Total-Asset is 0.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current LT-Debt-to-Total-Asset is 0.21 as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.